Table 2. Summary of Adverse Events During Treatment.

Adverse event	Mavacamten (n = 54)	Placebo (n = 27)
Total number of TEAEs	165	82
Patients with ≥1 TEAE, No. (%)	45 (83.3)	24 (88.9)
Patients with ≥1 treatment-related TEAE, No. (%)	11 (20.4)	9 (33.3)
Total No. of TESAEs	8	0
Patients with ≥1 TESAE, No. (%)	4 (7.4)	0
Atrial fibrillation	2 (3.7)	0
Atrial flutter	1 (1.9)	0
Sinus arrest	1 (1.9)	0
Sinus node dysfunction	1 (1.9)	0
Hypotension	1 (1.9)	0
Hemorrhoids	1 (1.9)	0
Ankle fracture	1 (1.9)	0
Patients with ≥1 related TESAE, No. (%)	0	0
Patients with ≥1 AESI, No. (%)	1 (1.9)	0

Abbreviations: AESI, adverse event of special interest; TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event.